Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52 week study evaluating the safety and efficacy of Simufilam 100mg tablets in subjects with mild-to-moderate Alzheimer's Disease (2023-2025)

Dr Rob Adam

Trials Medical Specialist

UQ Centre for Clinical Research

Faculty of Health, Medicine and Behavioural Sciences